Protagonist Therapeutics (PTGX) Research & Development (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Research & Development of $46.7 million for Q1 2026, up 0.82% sequentially from $46.4 million in Q4 2025, and up 30.22% YoY from $35.9 million in Q1 2025.
Protagonist Therapeutics (PTGX) Research & Development (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Research & Development for 12 years, with the latest figure at $46.7 million in Q1 2026.
- Quarterly Research & Development rose 30.22% year-over-year to $46.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170.1 million (up 21.28% YoY) and the FY2025 annual result came in at $159.3 million, up 15.32% from the prior year.
- Research & Development climbed to $46.7 million in Q1 2026 per PTGX's latest filing, from $46.4 million in the prior quarter.
- Over five years, Research & Development peaked at $46.7 million in Q1 2026 and troughed at $25.4 million in Q3 2022.
- A 5-year average of $34.7 million and a median of $34.6 million in 2022 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 49.8% in 2022, down 31.26% in 2022.
- Over 5 years, Research & Development stood at $29.9 million in 2022, then fell by 3.3% to $28.9 million in 2023, then advanced by 20.78% to $34.9 million in 2024, then soared by 32.82% to $46.4 million in 2025, then grew by 0.82% to $46.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $46.7 million, $46.4 million, and $40.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 42.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.06 Mn |
| Mar 31, 2026 | 46.74 Mn |
| Dec 31, 2025 | 46.36 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 37.04 Mn |
| Mar 31, 2025 | 35.89 Mn |
| Dec 31, 2024 | 34.90 Mn |
| Sep 30, 2024 | 35.97 Mn |
| Jun 30, 2024 | 33.52 Mn |
| Mar 31, 2024 | 33.73 Mn |
| Dec 31, 2023 | 28.90 Mn |
| Sep 30, 2023 | 30.66 Mn |
| Jun 30, 2023 | 33.18 Mn |
| Mar 31, 2023 | 27.42 Mn |
| Dec 31, 2022 | 29.88 Mn |
| Sep 30, 2022 | 25.40 Mn |
| Jun 30, 2022 | 34.61 Mn |
| Mar 31, 2022 | 36.32 Mn |
| Dec 31, 2021 | 38.37 Mn |
| Sep 30, 2021 | 36.96 Mn |